Pharmaceutical - Johnson & Johnson


Current filters:

Johnson & Johnson

Popular Filters

176 to 200 of 260 results

Pharmacyclics gets $50 milestone from J&J on ibrutinib progress


California, USA-based Pharmacyclics (Nasdaq: PCYC) says it that enrolment of the fifth patient in the…

FinancialibrutinibJanssenJohnson & JohnsonOncologyPharmaceuticalPharmacyclicsResearch

Pfizer and Janssen's bapineuzumab fails to meet one Ph III study endpoints for Alzheimer's


US drugs behemoth Pfizer (NYSE: PFE) revealed yesterday that the co-primary clinical endpoints, change…

bapineuzumabJanssenJohnson & JohnsonNeurologicalPfizerPharmaceuticalResearch

Johnson & Johnson 2nd-qtr earnings slump on charges and currencies


US health care giant Johnson & Johnson (NYSE: JNJ) yesterday announced second-quarter 2012 financial…

FinancialJohnson & JohnsonPharmaceutical

Genmab in collaboration with Janssen for DuoBody platform


Denmark-based Genmab A/S (OMX: GEN) says it has entered into a collaboration with Janssen Biotech, a…

BiotechnologyDuoBodyGenmabJanssen BiotechJohnson & JohnsonLicensingNovartisPharmaceutical

J&J'S rilpivirine also proven for combination HIV product, says IQWiG


Since the start of 2012, a new drug - rilpivirine from US health care giant Johnson & Johnson (NYSE:…

Anti-viralsEuropeEvipleraJohnson & JohnsonPharmaceuticalPricingRegulationrilpivirine

US priority review for two Xarelto sNDAs; one dropped


The US Food and Drug Administration has assigned a priority review designation to the supplemental New…

BayerCardio-vascularJanssenJohnson & JohnsonNorth AmericaPharmaceuticalRegulationXarelto

Johnson & Johnson pulls EU submission for Velcade use in NHL


The European Medicines Agency has been formally notified by US health care giant Johnson & Johnson's…

EuropeJanssen-CilagJohnson & JohnsonOncologyPharmaceuticalRegulationVelcade

Janssen buys Germany's CorImmun


US health care giant Johnson & Johnson's (NYSE: JNJ) European subsidiary Janssen-Cilag GmbH yesterday…

Cardio-vascularCorImmun GmbHJanssenJohnson & JohnsonMergers & AcquisitionsPharmaceutical

US physicians to increase use of Zytiga in chemo-naive prostate cancer patients


Physicians in the USA said they would use Zytiga (abiraterone acetate), from health care giant Johnson…

DendreonJanssenJohnson & JohnsonMarkets & MarketingNorth AmericaOncologyPharmaceuticalProvengeResearchZytiga

Janssen files for EU approval of canagliflozin in type 2 diabetes; Ferrer pulls Egrifta MAA


US health care giant Johnson & Johnson's (NYSE: JNJ) European subsidiary Janssen-Cilag International…

Anti-viralscanagliflozinDiabetesEgriftaEuropeFerrer InternacionalJanssenJohnson & JohnsonPharmaceuticalRegulation

Disappointing FDA views for Bayer's Xarelto and Pozen ulcer drug


Bayer HealthCare, a unit of Germany's Bayer (BAYN: DE) says that it has received a complete response…

BayerCardio-vascularGastro-intestinalsJohnson & JohnsonNorth AmericaPA32540PharmaceuticalPozenRegulationXarelto

Johnson & Johnson units file for new Zytiga use in USA and EU


Janssen Research & Development, a subsidiary of US drugs giant Johnson & Johnson (NYSE: JNJ), has submitted…

EuropeJanssenJohnson & JohnsonNorth AmericaOncologyPharmaceuticalRegulationZytiga

Five more drug majors join NIH initiative to speed therapeutic discovery


Five additional pharmaceutical companies have joined a US National Institutes of Health-led effort to…

Abbott LaboratoriesBristol-Myers SquibbGlaxoSmithKlineJohnson & JohnsonNorth AmericaPharmaceuticalResearchSanofi

Alkermes and J&J initiate Ph III trial of three-month Invega Sustenna


USA-based Alkermes (Nasdaq: ALKS) and partner health care giant Johnson & Johnson (NYSE: JNJ) have started…

AlkermesInvega SustennaJohnson & JohnsonNeurologicalPharmaceuticalResearch

US regulator puts conditions on Johnson & Johnson's proposed buy of Synthes


The US Federal Trade Commission will require health care giant Johnson & Johnson (NYSE: JNJ) to sell…

Johnson & JohnsonMergers & AcquisitionsNorth AmericaPharmaceuticalRegulationSynthes

ASCO 2012: "Show me the overall survival data," say analysts


The annual American Society of Clinical Oncology (ASCO) meeting, held this year in Chicago from June…

GenentechJohnson & JohnsonOncologyPharmaceuticalResearchRochetrastuzumab emtansineZytiga

More news at EULAR from Novartis, J&S and B-MS


Highlights presented at the annual congress of the European League Against Rheumatism (EULAR 2012), in…

Anti-Arthritics/RheumaticsBristol-Myers SquibbIlarisJohnson & JohnsonNovartisOrenciaPharmaceuticalResearchSimponi InjectionStelara Injection

Flood of new cancer drug data presented at ASCO; nearly 1,000 being tested


The annual prestigious American Society of Clinical Oncology (ASCO) meeting taking place in Chicago,…

afatinibBiotechnologyBoehringer IngelheimGenentechJanssenJohnson & JohnsonOncologyPharmaceuticalResearchRochetrastuzumab emtansineZytiga

Janssen files NDA with FDA for canagliflozin in type 2 diabetes


Janssen Research & Development, a subsidiary of health care giant Johnson & Johnson (NYSE: JNJ) has submitted…

canagliflozinDermatologicalsJanssenJohnson & JohnsonMitsubishi TanabeNorth AmericaPharmaceuticalRegulation

176 to 200 of 260 results

Back to top